Close

Here we select some of the classical literature in the field of chimeric antigen receptor technology. It is hoped that these reviews and research articles will help you to understand CAR technology quickly and keep up with the cutting edge development of this area.

Driving CAR T‑cells forward

Nature reviews Clinical oncology 13, no. 6 (2016): 370-383.

Jackson, Hollie J., Sarwish Rafiq, and Renier J. Brentjens.

This Review discussed those ongoing clinical trials that tests CAR designs directed at novel targets involved in haematological and solid malignancies, and present strategies that can increase the antitumour efficacy and safety of CAR T‑cell therapy. Given the fast-moving nature of this field, this paper only discuss studies with direct translational application currently or soon‑to‑be tested in the clinical setting.

CAR–T cells and solid tumors: tuning T cells to challenge an inveterate foe

Trends in molecular medicine 18, no. 7 (2012): 377-384.

Gilham, David E., Reno Debets, Martin Pule, Robert E. Hawkins, and Hinrich Abken.

This article reviewed the current clinical application of CAR–T cells and relate clinical efficacy and safety of CAR–T cell trials to parameters considered critical for CAR engineering, classified as the three T’s of CAR–T cell manipulation, that is T cell subset, T cell processing, and T cell engineering.

Adoptive cellular therapy:A race to the finish line

Science translational medicine 7.280 (2015): 280ps7-280ps7.

June, Carl H., Stanley R. Riddell, and Ton N. Schumacher.

This review summrized pharmaceutical and biotechnology companies, their cell type and indications in the area of adoptive cell therapy for cancer, infection disease and graf -versus-host disease (GVHD).

Prospects for gene-engineered T cell immunotherapy for solid cancers

Nature medicine 22.1 (2016): 26.

Klebanoff, Christopher A., Steven A. Rosenberg, and Nicholas P. Restifo.

This review offer the perspective on how expanding the use of genetically redirected T cells to treat the majority of patients with solid cancers will require major technical, manufacturing and regulatory innovations centered around the development of autologous gene therapies targeting private somatic mutations.

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

New England Journal of Medicine 375, no. 26 (2016): 2561-2569.

Brown, Christine E., Darya Alizadeh, Renate Starr, Lihong Weng, Jamie R. Wagner, Araceli Naranjo, Julie R. Ostberg et al.

This article reports a case of CAR-T therapy with positive results for the treatment of glioblastoma.

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

Blood 116, no. 20 (2010): 4099-4102.

Kochenderfer, James N., Wyndham H. Wilson, John E. Janik, Mark E. Dudley, Maryalice Stetler-Stevenson, Steven A. Feldman, Irina Maric et al.

This is the first reported case of effective clinical treatment with anti-CD19 CAR T cells.

Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.

Nature reviews Clinical oncology 10, no. 5 (2013): 267-276.

Kochenderfer, James N., and Steven A. Rosenberg.

This review summarized recent progress of anti-CD19 CAR-T technique for the treatment of B cell lymphoma.

Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.

Proceedings of the National Academy of Sciences 86, no. 24 (1989): 10024-10028.

Gross, Gideon, Tova Waks, and Zelig Eshhar.

This is the first paper that introduced the concept of chimeric antigen receptor

The Principles of Engineering Immune Cells to Treat Cancer

Cell 168, no. 4 (2017): 724-740.

Lim, W.A. and June, C.H.

This review summarized five major functional challenges for a therapeutic T cell and emerging new engineering solutions for addressing the functional challenges of anti-cancer T Cells.

CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond

Trends in Molecular Medicine (2017)

Chang, Ze Nan L., and Yvonne Y. Chen.

This review current understanding of the molecular properties of CARs, how this knowledge informs the rational design and characterization of novel receptors, the successes and shortcomings of CAR-T cells in the clinic, and emerging solutions for the continued improvement of CAR-T cell therapy

The pharmacology of second-generation chimeric antigen receptors

Nature reviews. Drug discovery 14.7 (2015): 499.

Van Der Stegen, Sjoukje JC, Mohamad Hamieh, and Michel Sadelain.

This review mainly talk about the combined activating and co-stimulatory domains of second-generation chimeric antigen receptors (CARs)

Therapeutic T cell engineering

Nature 545.7655 (2017): 423-431.

Sadelain, Michel, Isabelle Rivière, and Stanley Riddell

This is a latest review of t cell engineering technique. Mainly talk about how to engineer and manufacture better T cells, what t cell to engineer and where to apply enginnered T cell.

Driving CAR T‑cells forward

Nature reviews Clinical oncology 13, no. 6 (2016): 370-383.

Jackson, Hollie J., Sarwish Rafiq, and Renier J. Brentjens.

This Review discussed those ongoing clinical trials that tests CAR designs directed at novel targets involved in haematological and solid malignancies, and present strategies that can increase the antitumour efficacy and safety of CAR T‑cell therapy. Given the fast-moving nature of this field, this paper only discuss studies with direct translational application currently or soon‑to‑be tested in the clinical setting.

CAR–T cells and solid tumors: tuning T cells to challenge an inveterate foe

Trends in molecular medicine 18, no. 7 (2012): 377-384.

Gilham, David E., Reno Debets, Martin Pule, Robert E. Hawkins, and Hinrich Abken.

This article reviewed the current clinical application of CAR–T cells and relate clinical efficacy and safety of CAR–T cell trials to parameters considered critical for CAR engineering, classified as the three T’s of CAR–T cell manipulation, that is T cell subset, T cell processing, and T cell engineering.

Adoptive cellular therapy:A race to the finish line

Science translational medicine 7.280 (2015): 280ps7-280ps7.

June, Carl H., Stanley R. Riddell, and Ton N. Schumacher.

This review summrized pharmaceutical and biotechnology companies, their cell type and indications in the area of adoptive cell therapy for cancer, infection disease and graf -versus-host disease (GVHD).

Prospects for gene-engineered T cell immunotherapy for solid cancers

Nature medicine 22.1 (2016): 26.

Klebanoff, Christopher A., Steven A. Rosenberg, and Nicholas P. Restifo.

This review offer the perspective on how expanding the use of genetically redirected T cells to treat the majority of patients with solid cancers will require major technical, manufacturing and regulatory innovations centered around the development of autologous gene therapies targeting private somatic mutations.

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

New England Journal of Medicine 375, no. 26 (2016): 2561-2569.

Brown, Christine E., Darya Alizadeh, Renate Starr, Lihong Weng, Jamie R. Wagner, Araceli Naranjo, Julie R. Ostberg et al.

This article reports a case of CAR-T therapy with positive results for the treatment of glioblastoma.

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

Blood 116, no. 20 (2010): 4099-4102.

Kochenderfer, James N., Wyndham H. Wilson, John E. Janik, Mark E. Dudley, Maryalice Stetler-Stevenson, Steven A. Feldman, Irina Maric et al.

This is the first reported case of effective clinical treatment with anti-CD19 CAR T cells.

Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.

Nature reviews Clinical oncology 10, no. 5 (2013): 267-276.

Kochenderfer, James N., and Steven A. Rosenberg.

This review summarized recent progress of anti-CD19 CAR-T technique for the treatment of B cell lymphoma.

Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.

Proceedings of the National Academy of Sciences 86, no. 24 (1989): 10024-10028.

Gross, Gideon, Tova Waks, and Zelig Eshhar.

This is the first paper that introduced the concept of chimeric antigen receptor

The Principles of Engineering Immune Cells to Treat Cancer

Cell 168, no. 4 (2017): 724-740.

Lim, W.A. and June, C.H.

This review summarized five major functional challenges for a therapeutic T cell and emerging new engineering solutions for addressing the functional challenges of anti-cancer T Cells.

CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond

Trends in Molecular Medicine (2017)

Chang, Ze Nan L., and Yvonne Y. Chen.

This review current understanding of the molecular properties of CARs, how this knowledge informs the rational design and characterization of novel receptors, the successes and shortcomings of CAR-T cells in the clinic, and emerging solutions for the continued improvement of CAR-T cell therapy

The pharmacology of second-generation chimeric antigen receptors

Nature reviews. Drug discovery 14.7 (2015): 499.

Van Der Stegen, Sjoukje JC, Mohamad Hamieh, and Michel Sadelain.

This review mainly talk about the combined activating and co-stimulatory domains of second-generation chimeric antigen receptors (CARs)

Therapeutic T cell engineering

Nature 545.7655 (2017): 423-431.

Sadelain, Michel, Isabelle Rivière, and Stanley Riddell

This is a latest review of t cell engineering technique. Mainly talk about how to engineer and manufacture better T cells, what t cell to engineer and where to apply enginnered T cell.

Driving CAR T‑cells forward

Nature reviews Clinical oncology 13, no. 6 (2016): 370-383.

Jackson, Hollie J., Sarwish Rafiq, and Renier J. Brentjens.

This Review discussed those ongoing clinical trials that tests CAR designs directed at novel targets involved in haematological and solid malignancies, and present strategies that can increase the antitumour efficacy and safety of CAR T‑cell therapy. Given the fast-moving nature of this field, this paper only discuss studies with direct translational application currently or soon‑to‑be tested in the clinical setting.

CAR–T cells and solid tumors: tuning T cells to challenge an inveterate foe

Trends in molecular medicine 18, no. 7 (2012): 377-384.

Gilham, David E., Reno Debets, Martin Pule, Robert E. Hawkins, and Hinrich Abken.

This article reviewed the current clinical application of CAR–T cells and relate clinical efficacy and safety of CAR–T cell trials to parameters considered critical for CAR engineering, classified as the three T’s of CAR–T cell manipulation, that is T cell subset, T cell processing, and T cell engineering.

Adoptive cellular therapy:A race to the finish line

Science translational medicine 7.280 (2015): 280ps7-280ps7.

June, Carl H., Stanley R. Riddell, and Ton N. Schumacher.

This review summrized pharmaceutical and biotechnology companies, their cell type and indications in the area of adoptive cell therapy for cancer, infection disease and graf -versus-host disease (GVHD).

Prospects for gene-engineered T cell immunotherapy for solid cancers

Nature medicine 22.1 (2016): 26.

Klebanoff, Christopher A., Steven A. Rosenberg, and Nicholas P. Restifo.

This review offer the perspective on how expanding the use of genetically redirected T cells to treat the majority of patients with solid cancers will require major technical, manufacturing and regulatory innovations centered around the development of autologous gene therapies targeting private somatic mutations.

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

New England Journal of Medicine 375, no. 26 (2016): 2561-2569.

Brown, Christine E., Darya Alizadeh, Renate Starr, Lihong Weng, Jamie R. Wagner, Araceli Naranjo, Julie R. Ostberg et al.

This article reports a case of CAR-T therapy with positive results for the treatment of glioblastoma.

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

Blood 116, no. 20 (2010): 4099-4102.

Kochenderfer, James N., Wyndham H. Wilson, John E. Janik, Mark E. Dudley, Maryalice Stetler-Stevenson, Steven A. Feldman, Irina Maric et al.

This is the first reported case of effective clinical treatment with anti-CD19 CAR T cells.

Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.

Nature reviews Clinical oncology 10, no. 5 (2013): 267-276.

Kochenderfer, James N., and Steven A. Rosenberg.

This review summarized recent progress of anti-CD19 CAR-T technique for the treatment of B cell lymphoma.

Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.

Proceedings of the National Academy of Sciences 86, no. 24 (1989): 10024-10028.

Gross, Gideon, Tova Waks, and Zelig Eshhar.

This is the first paper that introduced the concept of chimeric antigen receptor

The Principles of Engineering Immune Cells to Treat Cancer

Cell 168, no. 4 (2017): 724-740.

Lim, W.A. and June, C.H.

This review summarized five major functional challenges for a therapeutic T cell and emerging new engineering solutions for addressing the functional challenges of anti-cancer T Cells.

CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond

Trends in Molecular Medicine (2017)

Chang, Ze Nan L., and Yvonne Y. Chen.

This review current understanding of the molecular properties of CARs, how this knowledge informs the rational design and characterization of novel receptors, the successes and shortcomings of CAR-T cells in the clinic, and emerging solutions for the continued improvement of CAR-T cell therapy

The pharmacology of second-generation chimeric antigen receptors

Nature reviews. Drug discovery 14.7 (2015): 499.

Van Der Stegen, Sjoukje JC, Mohamad Hamieh, and Michel Sadelain.

This review mainly talk about the combined activating and co-stimulatory domains of second-generation chimeric antigen receptors (CARs)

Therapeutic T cell engineering

Nature 545.7655 (2017): 423-431.

Sadelain, Michel, Isabelle Rivière, and Stanley Riddell

This is a latest review of t cell engineering technique. Mainly talk about how to engineer and manufacture better T cells, what t cell to engineer and where to apply enginnered T cell.

Driving CAR T‑cells forward

Nature reviews Clinical oncology 13, no. 6 (2016): 370-383.

Jackson, Hollie J., Sarwish Rafiq, and Renier J. Brentjens.

This Review discussed those ongoing clinical trials that tests CAR designs directed at novel targets involved in haematological and solid malignancies, and present strategies that can increase the antitumour efficacy and safety of CAR T‑cell therapy. Given the fast-moving nature of this field, this paper only discuss studies with direct translational application currently or soon‑to‑be tested in the clinical setting.

CAR–T cells and solid tumors: tuning T cells to challenge an inveterate foe

Trends in molecular medicine 18, no. 7 (2012): 377-384.

Gilham, David E., Reno Debets, Martin Pule, Robert E. Hawkins, and Hinrich Abken.

This article reviewed the current clinical application of CAR–T cells and relate clinical efficacy and safety of CAR–T cell trials to parameters considered critical for CAR engineering, classified as the three T’s of CAR–T cell manipulation, that is T cell subset, T cell processing, and T cell engineering.

Adoptive cellular therapy:A race to the finish line

Science translational medicine 7.280 (2015): 280ps7-280ps7.

June, Carl H., Stanley R. Riddell, and Ton N. Schumacher.

This review summrized pharmaceutical and biotechnology companies, their cell type and indications in the area of adoptive cell therapy for cancer, infection disease and graf -versus-host disease (GVHD).

Prospects for gene-engineered T cell immunotherapy for solid cancers

Nature medicine 22.1 (2016): 26.

Klebanoff, Christopher A., Steven A. Rosenberg, and Nicholas P. Restifo.

This review offer the perspective on how expanding the use of genetically redirected T cells to treat the majority of patients with solid cancers will require major technical, manufacturing and regulatory innovations centered around the development of autologous gene therapies targeting private somatic mutations.

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

New England Journal of Medicine 375, no. 26 (2016): 2561-2569.

Brown, Christine E., Darya Alizadeh, Renate Starr, Lihong Weng, Jamie R. Wagner, Araceli Naranjo, Julie R. Ostberg et al.

This article reports a case of CAR-T therapy with positive results for the treatment of glioblastoma.

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

Blood 116, no. 20 (2010): 4099-4102.

Kochenderfer, James N., Wyndham H. Wilson, John E. Janik, Mark E. Dudley, Maryalice Stetler-Stevenson, Steven A. Feldman, Irina Maric et al.

This is the first reported case of effective clinical treatment with anti-CD19 CAR T cells.

Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.

Nature reviews Clinical oncology 10, no. 5 (2013): 267-276.

Kochenderfer, James N., and Steven A. Rosenberg.

This review summarized recent progress of anti-CD19 CAR-T technique for the treatment of B cell lymphoma.

Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.

Proceedings of the National Academy of Sciences 86, no. 24 (1989): 10024-10028.

Gross, Gideon, Tova Waks, and Zelig Eshhar.

This is the first paper that introduced the concept of chimeric antigen receptor

The Principles of Engineering Immune Cells to Treat Cancer

Cell 168, no. 4 (2017): 724-740.

Lim, W.A. and June, C.H.

This review summarized five major functional challenges for a therapeutic T cell and emerging new engineering solutions for addressing the functional challenges of anti-cancer T Cells.

CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond

Trends in Molecular Medicine (2017)

Chang, Ze Nan L., and Yvonne Y. Chen.

This review current understanding of the molecular properties of CARs, how this knowledge informs the rational design and characterization of novel receptors, the successes and shortcomings of CAR-T cells in the clinic, and emerging solutions for the continued improvement of CAR-T cell therapy

The pharmacology of second-generation chimeric antigen receptors

Nature reviews. Drug discovery 14.7 (2015): 499.

Van Der Stegen, Sjoukje JC, Mohamad Hamieh, and Michel Sadelain.

This review mainly talk about the combined activating and co-stimulatory domains of second-generation chimeric antigen receptors (CARs)

Therapeutic T cell engineering

Nature 545.7655 (2017): 423-431.

Sadelain, Michel, Isabelle Rivière, and Stanley Riddell

This is a latest review of t cell engineering technique. Mainly talk about how to engineer and manufacture better T cells, what t cell to engineer and where to apply enginnered T cell.


Key Updates

Receive the latest news and insights to your inbox.